Cargando…
Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab
BACKGROUND: Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapi...
Autores principales: | Iannetta, Marco, Cesta, Novella, Stingone, Christof, Malagnino, Vincenzo, Teti, Elisabetta, Vitale, Pietro, De Simone, Giuseppe, Rossi, Benedetta, Ansaldo, Lorenzo, Compagno, Mirko, Spalliera, Ilaria, Di Lorenzo, Andrea, Landi, Doriana, Nicoletti, Carolina Gabri, Marfia, Girolama Alessandra, Andreoni, Massimo, Sarmati, Loredana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399651/ https://www.ncbi.nlm.nih.gov/pubmed/32777745 http://dx.doi.org/10.1016/j.msard.2020.102442 |
Ejemplares similares
-
T-cell responses to SARS-CoV-2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers
por: Iannetta, Marco, et al.
Publicado: (2021) -
Resistance to Ceftazidime/Avibactam in Klebsiella pneumoniae KPC-Producing Isolates: A Real-Life Observational Study
por: Campogiani, Laura, et al.
Publicado: (2023) -
Remdesivir Influence on SARS-CoV-2 RNA Viral Load Kinetics in Nasopharyngeal Swab Specimens of COVID-19 Hospitalized Patients: A Real-Life Experience
por: Campogiani, Laura, et al.
Publicado: (2023) -
HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy
por: Malagnino, Vincenzo, et al.
Publicado: (2019) -
Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment
por: Prezioso, Carla, et al.
Publicado: (2021)